April 19, 2024
Bio
Nature Cell Alzheimer’s drug gets approval for clinical trials in US
[THE INVESTOR] Nature Cell, the South Korean bio company, announced on Nov. 24 that its Alzheimer’s disease treatment candidate AstroStem has been approved by the US Food and Drug Administration to initiate the first and second stages of clinical trials.
AstroStem consists of stem cells derived from the patient’s own autologous adipose tissue, to be injected repeatedly into the vein.
“In animal testing carried out on our own, the drug candidate’s safety and efficacy have been confirmed,” said a company official.
“Following the approval, we will recruit patients in two hospitals in the US from the end of this year.”
By Hwang You-mee (glamazon@heraldcorp.com)
AstroStem consists of stem cells derived from the patient’s own autologous adipose tissue, to be injected repeatedly into the vein.
“In animal testing carried out on our own, the drug candidate’s safety and efficacy have been confirmed,” said a company official.
“Following the approval, we will recruit patients in two hospitals in the US from the end of this year.”
By Hwang You-mee (glamazon@heraldcorp.com)
